

October 30, 2014

Company Name: JAPAN TOBACCO INC.
Representative: Mitsuomi Koizumi, President, Chief Executive Officer and Representative Director
(Stock Code: 2914; Stock Exchange: Tokyo First Section)
Contact: Media and Investor Relations Division
Tel: +81-3-3582-3111

Notice Concerning Amendments to Earnings Forecasts of JT's Subsidiary

Japan Tobacco Inc. (JT) today announced that Torii Pharmaceutical Co., Ltd., a consolidated subsidiary of JT, amended the earnings forecasts for the December 2014 term (April 1, 2014 through December 31, 2014) as the attached sheet.

The effects of this amendment on JT's consolidated financial results will be immaterial.

(Attachment)

Reference: "Torii Amends Earnings Forecasts for Fiscal Year Ending December 31, 2014" (a material released by Torii Pharmaceutical Co., Ltd. as of October 30, 2014)

* * * * *

October 30, 2014

Torii Pharmaceutical Co., Ltd.

Torii Amends Earnings Forecasts for Fiscal Year Ending December 31, 2014

In consideration of the recent trend in earnings and other factors, Torii Pharmaceutical Co., Ltd. (“Torii”) has amended its earnings forecasts for the fiscal year ending December 31, 2014, which were announced on April 24, 2014, as described below.

1. Amendments to Earnings Forecasts for Fiscal Year Ending December 31, 2014 (April 1, 2014, through December 31, 2014)

	Net sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)	Net income per share (Yen)
Previous forecast (A)	42,900	2,700	2,800	1,600	56.54
New forecast (B)	43,500	3,500	3,600	2,000	70.67
Amount of change (B-A)	600	800	800	400	
Rate of change (%)	1.4	29.6	28.6	25.0	
(Reference) Actual cumulative amount for April to December 2013)	43,524	3,986	4,098	2,378	84.03

* The earnings forecasts for the fiscal year ending December 31, 2014, which is the transitional period for a change to the fiscal year end, represent the forecasts for a nine-month period (April 1, 2014, to December 31, 2014).

2. Reasons for Amendments

Net sales is now expected to be higher than the previously announced forecast figure because sales of products including Truvada® Tablets, an anti-HIV drug, and REMITCH® CAPSULES, an oral antipruritus drug for hemodialysis patients, are stronger than expected. Furthermore, on the profits front, although loss on retirement of non-current assets was recorded as extraordinary loss, some R&D expenses previously expected to occur in the current fiscal year are now expected to occur in the next fiscal year. As a result, operating income, ordinary income and net income are also expected to be higher than the previously announced forecast figures.

* The above-mentioned earnings forecasts are based on information available to Torii as of the date of this announcement. Actual business results may differ from the forecast figures herein.

[Reference: 12 months information]

	Net sales (Millions of yen)	Operating income (Millions of yen)	Ordinary income (Millions of yen)	Net income (Millions of yen)
Actual result from January to December 2013 (A)	55,291	3,621	3,738	2,335
Forecast from January to December 2014 (B)	58,085	4,501	4,625	2,974
Amount of change (B-A)	2,793	880	887	639
Rate of change (%)	5.1%	24.3%	23.7%	27.4%

<Method of calculating the amounts for 12 months>

(A) Figures for the actual results for the period from January to December 2013

Figure for January to March 2013 (Actual result for the fiscal year ended March 31, 2013 <12 months> – Actual result for the nine months ended December 31, 2012 <9 months>) + Figure for April to December 2013 (Actual result for the nine months ended December 31, 2013)

(B) Figures for the forecasts for the period from January to December 2014

Figure for January to March 2014 (Actual result for the fiscal year ended March 31, 2014 <12 months> – Actual result for the nine months ended December 31, 2013 <9 months>) + Figure for April to December 2014 (forecast for the fiscal year ending December 31, 2014)